Immunological Medicine最新文献_第9页

The role of toll-like receptors in peptic ulcer disease. toll样受体在消化性溃疡疾病中的作用。

IF 4.4

Immunological Medicine Pub Date : 2022-06-01 Epub Date: 2021-10-16 DOI: 10.1080/25785826.2021.1963190

Shizhu Jin, Narayan Nepal, Yang Gao

{"title":"The role of toll-like receptors in peptic ulcer disease.","authors":"Shizhu Jin, Narayan Nepal, Yang Gao","doi":"10.1080/25785826.2021.1963190","DOIUrl":"https://doi.org/10.1080/25785826.2021.1963190","url":null,"abstract":"Helicobacter pylori (HP) is the primary etiologic factor that induces events in the immune system that lead to peptic ulcers. Toll-like receptors (TLRs) are an important part of the innate immune system, as they play pivotal roles in pathogen-associated molecular pattern (PAMP) recognition of HP as well host-associated damage-associated molecular patterns (DAMPs). Recent advancements such as COX-2 production, LPS recognition through TLR2, CagL, and CagY protein of HP activating TLR5, TLR9 activation via type IV secretion system (T4SS) using DNA transfer, TLR polymorphisms, their adaptor molecules, cytokines, and other factors play a significant role in PUD. Thus, some novel PUD treatments including Chuyou Yuyang granules, function by TLR4/NF-κB signaling pathway suppression and TNF-α and IL-18 inhibition also rely on TLR signaling. Similarly glycyrrhetinic acid (GA) treatment activates TLR-4 in Ana-1 cells not via TRIF, but via MYD88 expression, which is significantly upregulated to cure PUD. Therefore, understanding TLR signaling complexity and its resultant immune modulation after host-pathogen interactions is pivotal to drug and vaccine development for other diseases as well including cancer and recent pandemic COVID-19. In this review, we summarize the TLRs and HP interaction; its pathophysiology-related signaling pathways, polymorphisms, and pharmaceutical approaches toward PUD.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39525896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Role of CD4⁺CD25⁺FOXP3⁺ T_Reg cells on tumor immunity. CD4+CD25+FOXP3+ TReg细胞在肿瘤免疫中的作用。

IF 4.4

Immunological Medicine Pub Date : 2022-06-01 Epub Date: 2021-09-08 DOI: 10.1080/25785826.2021.1975228

Agustinus Darmadi Hariyanto, Tiara Bunga Mayang Permata, Soehartati Argadikoesoema Gondhowiardjo

{"title":"Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity.","authors":"Agustinus Darmadi Hariyanto, Tiara Bunga Mayang Permata, Soehartati Argadikoesoema Gondhowiardjo","doi":"10.1080/25785826.2021.1975228","DOIUrl":"https://doi.org/10.1080/25785826.2021.1975228","url":null,"abstract":"Not all T cells are effector cells of the anti-tumor immune system. One of the subpopulations of CD4+ T cells that express CD25+ and the transcription factor FOXP3, known as Regulator T cells (TReg), plays an essential role in maintaining tolerance and immune homeostasis preventing autoimmune diseases, minimalize chronic inflammatory diseases by enlisting various immunoregulatory mechanisms. The balance between effector T cells (Teff) and regulator T cells is crucial in determining the outcome of an immune response. Regarding tumors, activation or expansion of TReg cells reduces anti-tumor immunity. TReg cells inhibit the activation of CD4+ and CD8+ T cells and suppress anti-tumor activity in the tumor microenvironment. In addition, TReg cells also promote tumor angiogenesis both directly and indirectly to ensure oxygen and nutrient transport to the tumor. There is accumulating evidence showing a positive result that removing or suppressing TReg cells increases anti-tumor immune response. However, depletion of TReg cells will cause autoimmunity. One strategy to improve or restore tumor immunity is targeted therapy on the dominant effector TReg cells in tumor tissue. Various molecules such as CTLA-4, CD4, CD25, GITR, PD-1, OX40, ICOS are in clinical trials to assess their role in attenuating TReg cells' function.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39413323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. 免疫检查点阻断治疗引起的免疫相关不良事件的免疫病理学基础。

IF 4.4

Immunological Medicine Pub Date : 2022-06-01 Epub Date: 2021-09-19 DOI: 10.1080/25785826.2021.1976942

Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Rena Morita, Toshihiko Torigoe

引用次数: 5

Obstetric anti-phospholipid syndrome: from pathogenesis to treatment. 产科抗磷脂综合征:从发病机理到治疗。

IF 4.4

Immunological Medicine Pub Date : 2022-06-01 Epub Date: 2021-09-01 DOI: 10.1080/25785826.2021.1969116

Kayoko Kaneko, Nobuaki Ozawa, Atsuko Murashima

引用次数: 6

Interactomic inhibition of Eomes in the nucleus alleviates EAE via blocking the conversion of Th17 cells into non-classic Th1 cells. 通过阻断Th17细胞向非经典Th1细胞的转化，细胞核中Eomes的相互作用抑制减轻了EAE。

IF 4.4

Immunological Medicine Pub Date : 2022-06-01 Epub Date: 2022-02-07 DOI: 10.1080/25785826.2022.2031812

Bo-Young Shin, Su-Hyeon Lee, Yuna Kim, Jaekyeung An, Tae-Yoon Park, Sang-Kyou Lee

{"title":"Interactomic inhibition of Eomes in the nucleus alleviates EAE via blocking the conversion of Th17 cells into non-classic Th1 cells.","authors":"Bo-Young Shin, Su-Hyeon Lee, Yuna Kim, Jaekyeung An, Tae-Yoon Park, Sang-Kyou Lee","doi":"10.1080/25785826.2022.2031812","DOIUrl":"https://doi.org/10.1080/25785826.2022.2031812","url":null,"abstract":"Th17 cells are implicated in the pathogenesis of several autoimmune diseases. During the inflammation, Th17 cells exposed to IL-12 can shift towards the Th1 phenotype. These shifted cells are defined as 'non-classic Th1 cells'. Th17-derived non-classic Th1 cells play a critical role in late-onset chronic inflammatory diseases and are more pathogenic than the unshifted Th17 cells. Eomes is a transcription factor highly expressed in non-classic Th1 cells. To study the functional role of Eomes without genetic alteration, novel recombinant protein, ntEomes-TMD, was generated by fusing TMD of Eomes and Hph-1-PTD that facilitate intracellular delivery of its cargo molecule. ntEomes-TMD was delivered into the nucleus of the cells without influencing the T cell activation and cytotoxicity. ntEomes-TMD specifically inhibited the Eomes- and ROR-γt-mediated transcription and suppressed the Th1 and Th17 differentiation. Interestingly, ntEomes-TMD blocked the generation of non-classic Th1 cells from Th17 cells, leading to the inhibition of IFN-γ and GM-CSF secretion. In EAE, ntEomes-TMD alleviated the symptoms of EAE, and the combination treatment using ntEomes-TMD and anti-IL-17 mAb together showed better therapeutic efficacy than anti-IL-17 mAb treatment. The results suggest that ntEomes-TMD can be a new therapeutic reagent for treating chronic inflammatory diseases associated with non-classic Th1 cells.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39600508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The impact of maternal exposure to antibiotics on the development of child gut microbiome. 母体接触抗生素对儿童肠道微生物群发育的影响。

IF 4.4

Immunological Medicine Pub Date : 2022-06-01 Epub Date: 2021-08-15 DOI: 10.1080/25785826.2021.1963189

Jun Miyoshi, Tadakazu Hisamatsu

{"title":"The impact of maternal exposure to antibiotics on the development of child gut microbiome.","authors":"Jun Miyoshi, Tadakazu Hisamatsu","doi":"10.1080/25785826.2021.1963189","DOIUrl":"https://doi.org/10.1080/25785826.2021.1963189","url":null,"abstract":"Antibiotics are widely prescribed for mothers in the peripartum period today. Approximately 40% of pregnant women at term are exposed to antibiotics. Antibiotics are useful against infectious conditions such as chorioamnionitis; however, they alter the maternal microbiome. The maternal microbiome, particularly the gut microbiome, is transmitted to their neonates and is one of the major sources that shape the child's gut microbiome. The gut microbiome early in life plays a crucial role in the development of the gut microbiome itself as well as the host health over the entire life. Microbes structure the commensal ecosystem in the host. Simultaneously, microbial components and metabolites influence the host organ functions including the immune system, and vice versa, the various factors of the host impact the microbiome. The alterations of the gut microbiome induced by antibiotics in mothers can lead to gut dysbiosis in children eventually resulting in chronic disease conditions including immune disorders. Knowledge of the lasting impacts of maternal peripartum exposure to antibiotics on the gut microbiome and health in offspring and reconsideration of the adequate use of antibiotics in clinical practice are needed. Avoiding and restoring neonatal dysbiosis following maternal antibiotics-induced dysbiosis could be a new preventive strategy for various diseases.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39322977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Immunouniverse of SARS-CoV-2 严重急性呼吸系统综合征冠状病毒2型的免疫宇宙

IF 4.4

Immunological Medicine Pub Date : 2022-05-02 DOI: 10.1080/25785826.2022.2066251

Dennis Jiménez, Marbel Torres Arias

引用次数: 8

Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review COVID-19疫苗的安全性、有效性和免疫原性系统回顾

IF 4.4

Immunological Medicine Pub Date : 2022-05-01 DOI: 10.1080/25785826.2022.2068331

Neelam Asghar, H. Mumtaz, Abdul Ahad Syed, Farea Eqbal, Reeju Maharjan, Aditya Bamboria, Manish Shrehta

{"title":"Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review","authors":"Neelam Asghar, H. Mumtaz, Abdul Ahad Syed, Farea Eqbal, Reeju Maharjan, Aditya Bamboria, Manish Shrehta","doi":"10.1080/25785826.2022.2068331","DOIUrl":"https://doi.org/10.1080/25785826.2022.2068331","url":null,"abstract":"Abstract The World Health Organization stated on 11 March 2020 that a coronavirus illness had been discovered in Wuhan, China in December 2019. Effective vaccinations are eagerly awaited as the global outbreak of COVID-19 continues. The aim is to evaluate the safety, effectiveness, and immunogenicity of Pfizer/AstraZeneca/Modera/Cansino vaccines against COVID-19. An electronic search on different databases yielded 12,907 articles. A total of 20 randomized and non-randomized, published, and ongoing trials were selected. Cochrane RoB version 2.0 was used to assess the authenticity of the studies. Of these 20 trials, three were conducted on Pfizer, three on AstraZeneca, three on Moderna, and two on the Cansino vaccine. These trials have reported promising results for the safety, efficacy, and immunogenicity of the respective vaccines. None of the trials have reported the efficacy and severe adverse outcomes for the Cansino vaccine, hindering its reliability as a safe vaccine against covid-19. Furthermore, the results of these trials have established Pfizer to be the most efficacious vaccine against covid-19, having an efficacy of 94.6%. A few severe adverse events were reported by the included trials. However, further systematic reviews are required to understand the respective vaccine profiles on Immuno-suppressive, organ transplants, and patients with other comorbidities.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43565304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Immune-mediated necrotizing myopathy which showed deposition of C5b-9 in the necrotic muscle fibers and was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins 免疫介导的坏死性肌病，坏死肌纤维中有C5b-9沉积，经高剂量糖皮质激素、他克莫司和静脉注射免疫球蛋白联合强化治疗成功

IF 4.4

Immunological Medicine Pub Date : 2022-04-07 DOI: 10.1080/25785826.2022.2060169

T. Shimada, M. Higashida-Konishi, M. Akiyama, S. Hama, K. Izumi, S. Matsubara, H. Oshima, Y. Okano

{"title":"Immune-mediated necrotizing myopathy which showed deposition of C5b-9 in the necrotic muscle fibers and was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins","authors":"T. Shimada, M. Higashida-Konishi, M. Akiyama, S. Hama, K. Izumi, S. Matsubara, H. Oshima, Y. Okano","doi":"10.1080/25785826.2022.2060169","DOIUrl":"https://doi.org/10.1080/25785826.2022.2060169","url":null,"abstract":"Abstract Currently, no standard treatment strategy has been established for immune-mediated necrotizing myopathy (IMNM). Here we present a case of IMNM which was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins. Her muscle weakness was rapidly progressive and severe so that she became bedridden one week after admission. She was complicated with dysphagia and had serum myogenic enzymes elevation, ventricular diastolic dysfunction, and interstitial lung disease. Serum anti-SRP antibody was positive and her muscle biopsy revealed many necrotic fibers with minimal inflammation. Further histological analysis demonstrated infiltration of phagocytic macrophages with deposition of membrane attack complex (C5b-9) in the necrotic muscle fibers, suggesting activation of complement pathway and macrophages as a pathomechanism of this disease. She was diagnosed as IMNM and was immediately initiated a combination therapy described above, which led to dramatic clinical improvements. Recent studies suggest that intravenous immunoglobulins and tacrolimus can inhibit the activation of complement pathway and macrophages. Our present case suggests that early initiation of intensive combined therapy including intravenous immunoglobulins and tacrolimus might be effective for preventing irreversible muscle damages by disrupting a pathogenic activation of complement and macrophages in IMNM.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42211111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus 抗组蛋白抗体在特发性和药物性狼疮中的临床应用

IF 4.4

Immunological Medicine Pub Date : 2022-04-06 DOI: 10.1080/25785826.2022.2060168

Adrian Y. S. Lee

引用次数: 3